We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » LAWMAKER'S REPORT BLASTS FDA FOR LAX ENFORCEMENT

LAWMAKER'S REPORT BLASTS FDA FOR LAX ENFORCEMENT

June 27, 2006

A key House Democrat is blasting the FDA's enforcement policies, arguing that the agency is falling down on the job in its efforts to protect public safety.

Rep. Henry Waxman (D-Calif.), a frequent agency critic, released a report June 26 alleging that the FDA's enforcement has been on the decline since the start of the Bush administration. The report, "Prescription for Harm: The Decline in FDA Enforcement Activity," maintains the agency has slashed the number of enforcement actions it has taken since 2000. The study also argues that FDA headquarters officials routinely rejected enforcement recommendations from career staff.

Specifically, the 15-month study found that the number of warning letters issued by the agency for violations of federal requirements fell by more than 50 percent since 2000, from 1,154 that year to 535 in 2005. During that same period, seizures of medical products dropped by 44 percent. Waxman's report also found that in at least 138 cases over the past five years, FDA failed to take action despite receiving recommendations from its field inspectors.

The report is available at http://www.democrats.reform.house.gov/Documents/20060626113852-23476.pdf (http://www.democrats.reform.house.gov/Documents/20060626113852-23476.pdf).

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Consortium Gets EU Funding to Develop Continuous Blood Pressure Monitoring Device

  • FDA Approves GSK’s Oral Drug for Chronic Kidney Disease-Related Anemia

  • Aspivix’s Carevix Cleared to Reduce Pain, Bleeding in Gynecological Procedures

  • FDA Warns That Energy Supplement Contains Active Cialis Ingredient

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing